Spdr S&P Biotech Etf

XBI-N

NYSEARCA:XBI

97.26
0.55 (0.56%)

Analysis and Opinions about XBI-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
October 10, 2018

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.

Show full opinionHide full opinion

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.

TOP PICK
TOP PICK
October 10, 2017

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

Show full opinionHide full opinion

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

COMMENT
COMMENT
June 29, 2017

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

Show full opinionHide full opinion

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

BUY
BUY
June 30, 2016

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

Show full opinionHide full opinion

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

Showing 1 to 4 of 4 entries
  • «
  • 1
  • »

Spdr S&P Biotech Etf(XBI-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Spdr S&P Biotech Etf is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Spdr S&P Biotech Etf(XBI-N) Frequently Asked Questions

What is Spdr S&P Biotech Etf stock symbol?

Spdr S&P Biotech Etf is a American stock, trading under the symbol XBI-N on the NYSE Arca (XBI). It is usually referred to as AMEX:XBI or XBI-N

Is Spdr S&P Biotech Etf a buy or a sell?

In the last year, there was no coverage of Spdr S&P Biotech Etf published on Stockchase.

Is Spdr S&P Biotech Etf a good investment or a top pick?

Spdr S&P Biotech Etf was recommended as a Top Pick by Cameron Hurst on 2018-10-10. Read the latest stock experts ratings for Spdr S&P Biotech Etf.

Why is Spdr S&P Biotech Etf stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Spdr S&P Biotech Etf worth watching?

In the last year, there was no coverage of Spdr S&P Biotech Etf published on Stockchase.

What is Spdr S&P Biotech Etf stock price?

On 2020-02-21, Spdr S&P Biotech Etf (XBI-N) stock closed at a price of $97.26.